• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [22349 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide - Benefit assessment according to §35a Social Code Book V]
2016     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) MicroVisualase Thermal Therapy System: MRI-guided laser ablation of neurologic tumourswave ablation for liver tumours
2016     NIHR Public Health Research (PHR) programme Interventions to promote or maintain physical activity during and after the transition to retirement: an evidence synthesis
2016     Institute for Clinical Effectiveness and Health Policy (IECS) [Alemtuzumab for multiple sclerosis]
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Evaluation of subcutaneous-lead implantable cardioverter-defibrillators]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Systematic guideline search and appraisal, as well as extraction of relevant recommendations, for a DMP "osteoporosis"]
2016     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Health Policy Advisory Committee on Technology (HealthPACT)
2016     Institute for Clinical Effectiveness and Health Policy (IECS) Brentuximab vedotin in lymphomas
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Use of radioactive seeds for the preoperative localization of non-palpable breast tumours]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Hyperbaric oxygen therapy for diabetic foot syndrome]
2016     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Radiofrequency ablation for treating nasal hypertrophy of the inferior turbinates
2016     Institute for Clinical Effectiveness and Health Policy (IECS) Endoscopic radiofrequency ablation (Secca Procedure) for the treatment of fecal incontinence
2016     HAYES, Inc. Balloon sinuplasty for treatment of chronic rhinosinusitis
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alirocumab - Addendum to Commission A15-47]
2016     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) SureFire Precision Chemoembolization Infusion system keeps drugs within liver tumours
2016     Institute for Clinical Effectiveness and Health Policy (IECS) Elastomeric drug infusion pumps
2016     HAYES, Inc. Comparative effectiveness of bivalirudin versus heparin monotherapy for percutaneous coronary intervention (PCI)
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Umeclidinium - Benefit assessment according to §35a Social Code Book V]
2016     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Argus II Retinal prosthesis
2016     Institute for Clinical Effectiveness and Health Policy (IECS) Autoantibody panel for autoimmune encephalitis
2016     HAYES, Inc. Electrical bone growth stimulation, invasive
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mepolizumab - Benefit assessment according to §35a Social Code Book V]
2016     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) BioZorb - an implantable device to delimit surgical site after lumpectomy in breast cancer
2016     Institute for Clinical Effectiveness and Health Policy (IECS) BAHA® bone-anchored hearing aid for the treatment of hearing loss
2016     HAYES, Inc. High-frequency chest wall compression for diseases other than cystic fibrosis
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ibrutinib - Benefit assessment according to §35a Social Code Book V]
2016     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Wireless technology for LV pacing without coronary sinus
2016     NIHR Health Technology Assessment programme Automated imaging technologies for the diagnosis of glaucoma: a comparative diagnostic study for the evaluation of the diagnostic accuracy, performance as triage tests and cost-effectiveness (GATE study)
2016     Institute for Clinical Effectiveness and Health Policy (IECS) Mutational screening of notch3 gene in the diagnosis of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukocencephalopathy (CADASIL)
2016     HAYES, Inc. Hyperbaric oxygen therapy for sudden sensorineural hearing loss
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fingolimod (new therapeutic indication) - Addendum to Commission A15-48]
2016     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Non-invasive open ventilation system
2016     NIHR Health Technology Assessment programme The feasibility of determining the effectiveness and cost-effectiveness of medication organisation devices compared with usual care for older people in a community setting: systematic review, stakeholder focus groups and feasibility randomised controlled trial
2016     Institute for Clinical Effectiveness and Health Policy (IECS) Radioembolization and chemoembolization with drug-eluting microspheres for the treatment of liver tumors
2016     HAYES, Inc. Indwelling pleural catheters for the management of malignant pleural effusions
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Parent information on newborn screening using pulse oximetry; addendum to commission S13-01]
2016     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Ovation iX Abdominal Stent Graft System
2016     Institute for Clinical Effectiveness and Health Policy (IECS) Hyperbaric oxygen therapy for the treatment of idiopathic sudden sensorineural hearing loss
2016     HAYES, Inc. Minimally invasive surgical (MIS) procedures for treatment of atrial fibrillation
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Implementation of guidelines - obstructive and beneficial factors]
2016     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Bioresorbable stents
2016     Institute for Clinical Effectiveness and Health Policy (IECS) Hydrophobic acrylic intraocular lenses in cataract surgery due to uveitis
2016     HAYES, Inc. Minimally invasive transforaminal lumbar interbody fusion (mitlif) versus open transforaminal lumbar interbody fusion (otlif) for treatment of lumbar disc disease: a review of reviews
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Afamelanotide - Assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2016     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) SentiMag and Sienna+ system for sentinel lymph node biopsy in breast cancer
2016     NIHR Health Services and Delivery Research programme Equity of utilisation of cardiovascular care and mental health services in England: a cohort-based cross-sectional study using small-area estimation
2016     Institute for Clinical Effectiveness and Health Policy (IECS) Three-dimensional electroanatomical mapping in arrhythmia ablation
2016     HAYES, Inc. Nitric oxide breath analysis for the management of asthma
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brivaracetam - Benefit assessment according to §35a Social Code Book V]
2016     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Ga-68 prostate specific membrane antigen (PSMA) PET/CT
2016     NIHR Horizon Scanning Centre (NIHR HSC) AXS 02 (zoledronic acid) for type I complex regional pain syndrome
2016     HAYES, Inc. Noninvasive computed fractional flow reserve from computed tomography (FFRCT) for coronary artery disease
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vismodegib - Benefit assessment according §35a Social Code Book V]
2016     NIHR Horizon Scanning Centre (NIHR HSC) Blinatumomab (Blincyto) for B-precursor acute lymphoblastic leukaemia minimal residual disease – patients in remission
2016     HAYES, Inc. Noninvasive electrical bone growth stimulators for spinal fusion or foot and ankle indications
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cobimetinib: addendum to commission A15-52]
2016     NIHR Horizon Scanning Centre (NIHR HSC) Duvelisib for relapsed chronic lymphocytic leukaemia – second and subsequent line
2016     HAYES, Inc. Patient-specific instruments for total knee arthroplasty: a review of reviews
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sacubitril/valsartan: addendum to commission A15-60]
2016     NIHR Horizon Scanning Centre (NIHR HSC) Duvelisib for relapsed follicular lymphoma - third and subsequent line
2016     HAYES, Inc. Ultrasound-guided high-intensity focused ultrasound for primary treatment of localized prostate cancer
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rilpivirine (new therapeutic indication): addendum to commisison A15-55]
2016     NIHR Horizon Scanning Centre (NIHR HSC) Lenvatinib (Lenvima) for unresectable hepatocellular carcinoma – first line
2016     HAYES, Inc. 5-aminolevulinic acid photodynamic therapy versus carbon dioxide laser ablation for the treatment of condylomata acuminata
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Crizotinib: addendum to commission A15-59]
2016     NIHR Horizon Scanning Centre (NIHR HSC) Masitinib for relapsed or refractory peripheral T-cell lymphoma
2016     HAYES, Inc. Amniotic tissue–derived allografts for treatment of plantar fasciitis
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide: addendum to commission A15-61]
2016     NIHR Health Technology Assessment programme The Head Injury Transportation Straight to Neurosurgery (HITS-NS) randomised trial: a feasibility study
2016     NIHR Health Services and Delivery Research programme Outpatient services and primary care: scoping review, substudies and international comparisons
2016     HAYES, Inc. Bupivacaine liposome injectable suspension (Exparel; Pacira Pharmaceuticals Inc.) for treatment of postoperative pain in abdominal surgeries
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ramucirumab (new therapeutic indication): benefit assessment according to §35a Social Code Book V]
2016     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Ursodeoxycholic acid (Ursofalk®)
2016     HAYES, Inc. Carbon dioxide (CO2) laser ablation versus other surgical treatment of condylomata acuminata
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin: benefit assessment according to §35a Social Code Book V]
2016     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Eribulin mesilate (Halaven®)
2016     HAYES, Inc. Fecal microbiota transplant for refractory or recurrent Clostridium difficile infection in adults
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin/metformin: benefit assessment according to §35a Social Code Book V]
2016     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Sorafenib (Nexavar®)
2016     HAYES, Inc. Intersitial brachytherapy for the treatment of nonmelanoma skin cancer
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ramucirumab (new therapeutic indication): benefit assessment according to §35a Social Code Book V]
2016     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Ulipristal acetate (Esmya®)
2016     Agency for Healthcare Research and Quality (AHRQ) Omega-3 fatty acids and cardiovascular disease: an updated systematic review
2016     HAYES, Inc. Laser balloon ablation for treatment of atrial fibrillation
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Osimertinib: benefit assessment according to §35a Social Code Book V]
2016     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Prucalopride (Resolor®)
2016     Agency for Healthcare Research and Quality (AHRQ) Strategies to de-escalate aggressive behavior in psychiatric patients
2016     HAYES, Inc. Low frequency right transcranial magnetic stimulation for major depressive disorder
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ibrutinib - addendum to commission A16-04]
2016     NIHR Horizon Scanning Centre (NIHR HSC) Lefitolimod for extensive small cell lung cancer – maintenance therapy
2016     Health Quality Ontario (HQO) Composite tissue transplant of hand or arm: a health technology assessment
2016     HAYES, Inc. Magnetic resonance-guided focused ultrasound therapy (ExAblate 2000; InSightec Ltd.) for ablation of uterine fibroids
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Necitumumab - Benefit assessment according to §35a Social Code Book V]
2016     NIHR Health Technology Assessment programme Concordance in diabetic foot ulceration: a cross-sectional study of agreement between wound swabbing and tissue sampling in infected ulcers
2016     NIHR Health Technology Assessment programme The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model
2016     NIHR Horizon Scanning Centre (NIHR HSC) Fostamatinib for chronic immune thrombocytopenic purpura
2016     Health Quality Ontario (HQO) Retinal prosthesis system for advanced retinitis pigmentosa: a health technology assessment
2016     HAYES, Inc. NanoKnife system for irreversible electroporation treatment of locally advanced pancreatic cancer
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ticagrelor (new therapeutic indication): benefit assessment according to §35a Social Code Book V]
2016     NIHR Horizon Scanning Centre (NIHR HSC) Daratumumab with bortezomib and dexamethasone for relapsed or refractory multiple myeloma – second line